Objectives-To compare outcomes from accelerated alteplase (recombinant tissue plasminogen activator, t-PA) and streptokinase use in acute myocardial infarction. Methods-Review of available studies identified by Medline and other literature searches that met the criteria of being a prospective, randomised clinical trial enrolling over 1000 patients with acute myocardial infarction. The studies had to contain an intervention arm comprising accelerated infusion t-PA, or an intervention arm comprising streptokinase provided accelerated t-PA that was compared in the same trial. Interventions compared were streptokinase 1.5 million units given over one hour compared with accelerated t-PA infusion, with concomitant use of aspirin and heparin, and main outcome measure of 30 day mortality. Results-Four studies met prespecified criteria, these being the GUSTO I, GUSTO Ilb Angioplasty Substudy, GUSTO III, and COBALT trials. There was a total study population of 64 387 patients of whom 20 251 received streptokinase, 19 474 received t-PA, with others receiving different treatment. Pooled data show that accelerated t-PA produces a marginal 30 day mortality advantage compared with streptokinase (6.6% v 7.3%, p = 0.02, Bonferroni adjusted p = 0.12, that is borderline significance, relative risk 0.918, 95% confidence interval 0.854 to 0.986). Any benefit is attributable entirely to patients recruited in the United States in the GUSTO I study. There is an increased incidence of stroke with t-PA. Conclusions-The data do not consistently show a 30 day mortality benefit from using t-PA compared with streptokinase in acute myocardial infarction, but do show increased risk of stroke. Streptokinase can be considered the thrombolytic agent of choice. ( Accid Emerg Med 1999;16:407-41 1) 
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Keywords: acute myocardial infarct; thrombolysis; streptokinase; t-PA Thrombolysis is part of standard treatment for acute myocardial infarction, however there is controversy as to the preferred agent to use.
The GUSTO I trial' included an accelerated alteplase (recombinant tissue plasminogen activator, t-PA) infusion arm which showed a 30 day survival benefit compared with streptokinase, achieved at a cost of an excess of strokes. Although there is controversy regarding this conclusion,2" there is the perception that t-PA is better than streptokinase, but that its higher cost precludes more widespread use.4
Subsequent trials5 in comparable groups of patients have included identical t-PA treatment arms to that used in GUSTO I.l The purpose of this study is to incorporate these additional data to compare outcomes from accelerated t-PA and streptokinase use in acute myocardial infarction.
Methods
Articles were identified by a search to June 1998 of Medline, The Cochrane Library database, and Emergency Medicine Abstracts. Search term used were "myocardial infarct and thrombolysis", "myocardial infarct and streptokinase", and "myocardial infarct and t-PA". Articles obtained were further checked to obtain relevant citations, and the index of a number of major publications were searched manually.
The primary data were obtained from trials meeting the following criteria:
(1) Study population of over 1000 patients with acute myocardial infarction defined by electrocardiographic criteria.
(2) One intervention arm comprising accelerated infusion t-PA (given as a 15 mg bolus, followed by 0.75 mg/kg up to 50 mg over 30 minutes, then 0.5 mg/kg up to 35 mg over 60 minutes).
(3) One intervention arm comprising streptokinase 1.5 million units given over one hour, provided accelerated t-PA used in the same trial.
(4) Thirty day mortality as a primary outcome measure.
(5) A number of features of GUSTO I warrant comment.' 910 The two arms containing t-PA gave discordant results. In the accelerated infusion given over 90 minutes, 65 mg was given in the first 30 minutes and 82.5 mg by 60 minutes. This compares with the combination t-PA/streptokinase arm where 50 mg of t-PA was given by 30 minutes and 78 mg by 60 minutes. Although this is a similar infusion rate, the 30 day mortality was significantly different, being 6.3% with accelerated t-PA compared with 7.0% with t-PA/streptokinase (risk reduction 10%, 95% CI 0.8 to 19 .2, p = 0.04) despite similar patency at 90 minutes of 81% and 73%. The combination t-PA/streptokinase arm gave a better outcome compared with streptokinase in non-United States patients but gave the worst outcome in patients from the United States. Streptokinase gave reduced patency yet similar mortality compared with the combination t-PA/streptokinase group (see tables 1 and 2).
United States recruitment was a significant predictor of improved survival yet combined TIMI grade 2 or 3 patency rates were similar between United States and non-United States patients in GUSTO 11 (see table 1). Despite improved early patency with t-PA in GUSTO I, there was no improvement in global ejection fraction at 90 minutes nor at 5-7 days.9 The survival curves began to diverge at 6-8 hours, well after the observed transient improvement in coronary artery patency.
The GUSTO I trial was not blinded as to treatment given. There were substantial protocol violations as to whether heparin was given at all and by which route, and large variations in other non-protocol medical treatments given.1 l The survival advantage attributable to United States recruitment is apparent only in the t-PA arm and not the other three treatment groups. This intragroup survival advantage for t-PA approximates the overall t-PA versus streptokinase advantage.2 It is plausible that factors unrelated to the choice of thrombolytic agent produced a superior result that has been attributed to use of accelerated t-PA.
The use of angioplasty and bypass surgery was similar between the four treatment groups in GUSTO I, however the rate among United States patients was 31% and 13%, respectively, compared with 10% and 3% for non-United States patients.' 9 10 Although it has been speculated that this excess of intervention did not contribute to the survival difference among United States patients, the variables were not controlled for. The possibility that more frequent revacularisation procedures, together with other unmeasured differences in care provided to United States patients, resulted in improved survival cannot be excluded.'0 Among those in cardiogenic shock there was also a greater rate of revascularisation and surgical intervention in the group from the United States which did result in a significantly lower 30 day mortality.36 Conversely, the COBALT trial authors speculated that the lower rate of revascularisation procedures was a reason why the same t-PA treatment regimen used in the COBALT trial gave a less favourable outcome.7
A limitation of this analysis is that streptokinase data are available from only one trial. It is not appropriate to pool data from previous trials using streptokinase without an accelerated t-PA arm. In contrast, the studies using t-PA were either done by the same group (GUSTO)' 5 6 or used an identical protocol (COBALT).7 It is notable that although there have been extensive efforts by the pharmaceutical industry to sponsor and promote trials using t-PA, there has been little comparable effort with streptokinase despite evidence indicating that accelerated infusions are also superior to standard administration. 37 38 Finally, there is the question of what survival benefit can be expected from hastening early reperfusion with t-PA. The Fibrinolytic Therapy Trialists' Collaborative Group concluded that each hour of delay is associated with an increase in 30 day mortality of 1.6 +/-0.6 per 1000 patients.39 Accelerated t-PA achieves patency up to one hour earlier than streptokinase, yet GUSTO Il suggested a benefit of 10 per 1000 patients, which is inconsistent and somewhat implausible.3
It is not disputed that there are more strokes with t-PA use compared with streptokinase, with an excess of 3:1000 among patients treated in GUSTO I.' A study of 71 073 patients in the national registry of t-PA use for myocardial infarction in the United States sponsored by Genentech Inc, manufacturer of t-PA, documents a higher rate of intracranial haemorrhage in community practice (0.9%) compared with that reported in GUSTO I (0.7%).4°Cost considerations would further establish streptokinase as the preferred agent (A$201.68 v A$2245.04 for t-PA as listed in the Australian Schedule of Pharmaceutical Benefits, February 1999).
In conclusion, existing data do not convincingly demonstrate a benefit from using t-PA compared with streptokinase in acute myocardial infarction. No advantage was shown by the ISIS-3"2 and GISSI-2"' trials that used a three or four hour t-PA infusion. In subsequent trials using an accelerated infusion regimen, only one of five arms showed a benefit from t-PA.' 5-7 10 Streptokinase can be considered the thrombolytic agent of choice for use in acute myocardial infarction based on available evidence as to efficacy and risk. 
